MannKind Corporation (MNKD)
Largest Insider Buys in Sector
MNKD Stock Price History Chart
MNKD Stock Performance
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with …
Insider Activity of MannKind Corporation
Over the last 12 months, insiders at MannKind Corporation have bought $0 and sold $3.22M worth of MannKind Corporation stock.
On average, over the past 5 years, insiders at MannKind Corporation have bought $337,420 and sold $1.44M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,147 shares for transaction amount of $9,221 was made by Castagna Michael (Chief Executive Officer) on 2022‑07‑31.
List of Insider Buy and Sell Transactions, MannKind Corporation
| 2024-11-15 | Sale | director | 67,539 0.0234% | $6.76 | $456,564 | +1.32% | ||
| 2024-11-06 | Sale | Chief People & Workpl Officer | 55,000 0.0199% | $7.34 | $403,700 | -5.65% | ||
| 2024-09-03 | Sale | Chief People & Workpl Officer | 25,000 0.0094% | $6.26 | $156,500 | +8.22% | ||
| 2024-08-30 | Sale | Chief People & Workpl Officer | 80,000 0.0294% | $6.33 | $506,050 | +4.79% | ||
| 2024-08-29 | Sale | Chief Executive Officer | 85,106 0.0308% | $6.30 | $536,168 | +3.55% | ||
| 2024-08-29 | Sale | EVP Special Projects | 5,055 0.0017% | $5.94 | $30,027 | +3.55% | ||
| 2024-08-29 | Sale | EVP Genl Counsel & Secretary | 5,553 0.0019% | $5.94 | $32,985 | +3.55% | ||
| 2024-07-16 | Sale | EVP Special Projects | 2,836 0.0012% | $5.93 | $16,817 | +4.83% | ||
| 2024-07-16 | Sale | EVP Genl Counsel & Secretary | 3,115 0.0013% | $5.93 | $18,472 | +4.83% | ||
| 2024-05-21 | Sale | EVP Special Projects | 25,952 0.0094% | $4.66 | $120,936 | +25.11% | ||
| 2024-05-21 | Sale | EVP Genl Counsel & Secretary | 23,537 0.0085% | $4.66 | $109,682 | +25.11% | ||
| 2024-05-13 | Sale | EVP Special Projects | 3,618 0.0013% | $4.31 | $15,594 | +31.97% | ||
| 2024-05-13 | Sale | EVP Genl Counsel & Secretary | 3,047 0.0011% | $4.31 | $13,133 | +31.97% | ||
| 2023-12-15 | Sale | Chief Executive Officer | 90,482 0.0341% | $4.00 | $361,928 | +17.87% | ||
| 2023-12-14 | Sale | Chief Executive Officer | 110,000 0.0409% | $4.00 | $440,000 | +16.69% | ||
| 2023-11-01 | Sale | Chief Executive Officer | 10,000 0.0039% | $4.25 | $42,500 | +10.42% | ||
| 2023-10-02 | Sale | Chief Executive Officer | 10,000 0.0038% | $4.08 | $40,800 | +5.09% | ||
| 2023-09-01 | Sale | Chief Executive Officer | 10,000 0.0037% | $4.61 | $46,100 | -9.72% | ||
| 2023-08-28 | Sale | EVP Genl Counsel & Secretary | 8,100 0.003% | $4.78 | $38,738 | -12.26% | ||
| 2023-08-01 | Sale | Chief Executive Officer | 10,000 0.0039% | $4.57 | $45,686 | -6.57% |
Insider Historical Profitability
| Castagna Michael | Chief Executive Officer | 2294836 0.8321% | $6.84 | 20 | 16 | +8.74% |
| Binder Steven B. | director | 1075026 0.3898% | $6.84 | 9 | 6 | +23.89% |
| Tross Stuart A | Chief People & Workpl Officer | 967191 0.3507% | $6.84 | 12 | 3 | +16.1% |
| MANN ALFRED E | Chairman & CEO | 74750000 27.1051% | $6.84 | 15 | 0 | <0.0001% |
| Edstrom Hakan | President & CEO | 1060302 0.3845% | $6.84 | 10 | 15 | +5.87% |
Institutional Investor Ownership
| BlackRock | $97.97M | 7.94 | 21.63M | -3% | -$3.03M | <0.01 | |
| The Vanguard Group | $68.59M | 5.56 | 15.14M | -0.71% | -$488,782.47 | <0.01 | |
| State Street | $54.09M | 4.39 | 11.94M | -7.72% | -$4.53M | <0.01 | |
| Nitorum Fund LP | $45.66M | 3.7 | 10.08M | -6.94% | -$3.41M | 4.65 | |
| Avoro Capital Advisors Llc | $40.77M | 3.31 | 9M | 0% | +$0 | 0.49 |